Metabolic profiling of Alzheimer's disease brains

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Inoue, Koichi ^a   Tsutsui, Haruhito ^a   Akatsu, Hiroyasu ^b,c   Hashizume, Yoshio ^b   Matsukawa, Noriyuki ^c   Yamamoto, Takayuki ^b   Toyo'Oka, Toshimasa ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b Fukushimura Hospital   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ORNITHINE; ORNITHINE DECARBOXYLASE; POLYAMINE;

AGED; ALZHEIMER DISEASE; BRAIN; FEMALE; HUMAN; MALE; METABOLISM; METABOLOME; VERY ELDERLY; ARTICLE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOGENIC POLYAMINES; BRAIN; FEMALE; HUMANS; MALE; METABOLOME; ORNITHINE; ORNITHINE DECARBOXYLASE;

EID: 84881596428     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02364     Document Type: Article

References (65)

1. Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804 (2012).
2. Aisen, P. S. et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 76, 280-286 (2011).
3. Ringman, J. M. et al. Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 33, 1-5 (2012).
4. Mattsson, N. et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 78, 468-476 (2012).
5. Yang et al. Quantifying the pathophysiological timeline of Alzheimer's disease. J. Alzheimers Dis. 26, 745-753 (2011).
6. Vemuri, P. et al. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 75, 143-151 (2010).
7. Tauber, C. et al. Brain [18F]FDDNP Binding and Glucose Metabolism in Advanced Elderly Healthy Subjects and Alzheimer's Disease Patients. J. Alzheimers Dis. in press (2013).
8. Wirth, M. et al. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not b-amyloid in cognitively normal older individuals. J. Neurosci. 33, 5553-5563 (2013).
9. Mosconi, L., Andrews, R. D. & Matthews, D. C. Comparing Brain Amyloid Deposition, Glucose Metabolism, and Atrophy in Mild Cognitive Impairment with and without a Family History of Dementia. J. Alzheimers Dis. 35, 509-524 (2013).
10. Haight, T. J. et al. Relative contributions of biomarkers in Alzheimer's disease. Ann. Epidemiol. 22, 868-875 (2012).
11. Mishur, R. J. & Rea, S. L. Applications of mass spectrometry to metabolomics and metabonomics: detection of biomarkers of aging and of age-related diseases. Mass Spectrom. Rev. 31, 70-95 (2012).
12. Chan, R. B. et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J. Biol. Chem. 287, 2678-2880 (2012).
13. Astarita, G. et al. Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer's disease. PLoS One 6, e24777 (2011).
14. Hejazi, L. et al. Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer's disease brains. Biochem. J. 438, 165-175 (2011).
15. Sato, Y. et al. Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J. Lipid Res. 53, 567-576 (2012).
16. Kaddurah-Daouk, R. et al. Metabolomic changes in autopsy-confirmed Alzheimer's disease. Alzheimers Dement. 7, 309-317 (2011).
17. Greenberg, N. et al. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis 30, 1235-1239 (2009).
18. Czech, C. et al. Metabolite profiling of Alzheimer's disease cerebrospinal fluid. PLoS One 7, e31501 (2012).
19. Li, N. J. et al. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Clin. Biochem. 43, 992-997 (2010).
20. Tsutsui, H. et al. Practical analytical approach for the identification of biomarker candidates in prediabetic state based upon metabonomic study by ultraperformance liquid chromatography coupled to electrospray ionization time-of-flight mass spectrometry. J. Proteome Res. 9, 3912-3922 (2010).
21. Tsutsui, H. et al. Biomarker discovery in biological specimens (plasma, hair, liver and kidney) of diabetic mice based upon metabolite profiling using ultra-performance liquid chromatography with electrospray ionization time-of-flight mass spectrometry. Clin. Chim Acta 412, 861-872 (2011).
22. Guo, S. et al. UHPLC-TOFMS coupled with chemometric method as a powerful technique for rapid exploring of differentiating components between two Ziziphus species. J. Sep. Sci. 34, 659-666 (2011).
23. Li, S. L. et al. A novel strategy to rapidly explore potential chemical markers for the discrimination between raw and processed Radix Rehmanniae by UHPLC-TOFMS with multivariate statistical analysis. J. Pharm. Biomed. Anal. 51, 812-823 (2010).
24. Sugiura, K., Min, J. Z., Toyo'oka, T. & Inagaki, S. Rapid, sensitive and simultaneous determinationoffluorescence-labeled polyaminesinhuman hair by high-pressure liquid chromatography coupled with electrospray-ionization time-of-flight mass spectrometry. J. Chromatogr. A 1205, 94-102 (2008).
25. Min, J. Z. et al. Simultaneous determination of polyamines in human nail as 4-(N, N-dimethylaminosulfonyl)-7-fluoro-2, 1, 3-benzoxadiazole derivatives by nano-flow chip LC coupled with quadrupole time-of-flight tandem mass spectrometry. Clin. Chim. Acta 412, 98-106 (2011).
26. Fagan, A. M. & Perrin, R. J. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark. Med. 6, 455-476 (2012).
27. Andreasson, U. et al. Analytical aspects of molecular Alzheimer's disease biomarkers. Biomark. Med. 6, 377-389 (2012).
28. Hampel, H., Lista, S. & Khachaturian, Z. S. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement. 8, 312-336 (2012).
29. Di Carlo, M., Giacomazza, D. & San Biagio, P. L. Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools. J. Phys. Condens. Matter. 24, 244102 (2012).
30. Myint, K. T. et al. Quantitative profiling of polar cationic metabolites in human cerebrospinal fluid by reversed-phase nanoliquid chromatography/mass spectrometry. Anal. Chem. 81, 1121-1129 (2009).
31. Han, X. et al. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 6, e21643 (2011).
32. Graham, S. F. et al. Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease. Anal. Chem. 85, 1803-1811 (2013).
33. Veloso, A. et al. Distribution of lipids in human brain. Anal. Bioanal. Chem. 401, 89-101 (2011).
34. Grimm, M. O. et al. From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. J. Chromatogr. A 1218, 7713-7722 (2011).
35. Liu, C. C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. in press (2013).
36. Alonso Vilatela, M. E., López-López, M. & Yescas-Gómez, P. Genetics of Alzheimer's disease. Arch. Med. Res. 43, 622-6231 (2012).
37. Kline, A. Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease. Alzheimers Res. Ther. 4, 32 (2012).
38. Elias-Sonnenschein, L. S., Bertram, L. & Visser, P. J. Relationship between genetic risk factors and markers for Alzheimer's disease pathology. Biomark. Med. 6, 477-495 (2012).
39. Sheline, Y. I. & Raichle, M. E. Resting state functional connectivity in preclinical Alzheimer's disease. Biol. Psychiatry in press (2013).
40. Honjo, K., Black, S. E. & Verhoeff, N. P. Alzheimer's disease, cerebrovascular disease, and the b-amyloid cascade. Can. J. Neurol. Sci. 39, 712-728 (2012).
41. Catricala, S., Torti, M. & Ricevuti, G. Alzheimer disease and platelets: how's that relevant. Immun. Ageing 9, 20 (2012).
42. Schenk, D., Basi, G. S. & Pangalos, M. N. Treatment strategies targeting amyloid b-protein. Cold Spring Harb. Perspect. Med. 2, a006387 (2012).
43. Nankai, M., Klarica, M., Fage, D. & Carter, C. The pharmacology of native N-methyl-D-aspartate receptor subtypes: different receptors control the release of different striatal and spinal transmitters. Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 35-64 (1998).
44. Takano, K., Ogura, M., Nakamura, Y. & Yoneda, Y. Neuronal and glial responses to polyamines in the ischemic brain. Curr. Neurovasc. Res. 2, 213-223 (2005).
45. Igarashi, K. & Kashiwagi, K. Modulation of cellular function by polyamines. Int. J. Biochem. Cell Biol. 42, 39-51 (2010).
46. Paschen, W. Polyamine metabolism in different pathological states of the brain. Mol. Chem. Neuropathol. 16, 241-271 (1992).
47. Reisberg, B. et al. Memantine in moderater-to-severe Alzheimer's disease. N. Engl. J. Med. 348, 1333-1341 (2003).
48. Cacabelos, R., Takeda, M. & Winblad, B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Int. J. Geriatr. Psychiatry 14, 3-47 (1999).
49. Verges, J. et al. Opposing synaptic regulation of amyloid-b metabolism byNMDA receptors in vivo. J. Neurosci. 31, 11328-11337 (2011).
50. Malinow, R. New developments on the role of NMDA receptors in Alzheimer's disease. Curr. Opin. Neurobiol. 22, 559-563 (2012).
51. Williams, K. et al. Sensitivity of the N-methyl-d-aspartate receptor to polyamines is controlled by NR2 subunits. Mol. Pharmacol. 45, 803-809 (1994).
52. Ragnarsson, L., Mortensen, M., Dodd, P.R. & Lewis, R. J. Spermine modulation of the glutamate (NMDA) receptor is differentially responsive to conantokins in normal and Alzheimer's disease human cerebral cortex. J. Neurochem. 81, 765-779 (2002).
53. Yatin, S. M. et al. Alzheimer's amyloid beta-peptide associated free radicals increase rat embryonic neuronal polyamine uptake and ornithine decarboxylase activity: protective effect of vitamin E. Neurosci. Lett. 263, 17-20 (1999).
54. Yatin, S. M. et al. Role of spermine in amyloid beta-peptide-associated free radical-induced neurotoxicity. J. Neurosci. Res. 63, 395-401 (2001).
55. Mäkitie, L. T. et al. Brain neurons express ornithine decarboxylase-activating antizyme inhibitor 2 with accumulation in Alzheimer's disease. Brain Pathol. 20, 571-580 (2010).
56. Akatsu, H. Collaboration between Fukushimura Brain Bank, based in a private geriatric hospital and a national/international network. Brain Nerve. (Japanese) 62, 1043-1052 (2010).
57. Ossenkoppele, R. et al. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology in press (2012).
58. Jagust, W. J. & Landau, S. M. Apolipoprotein E, Not fibrillar b-amyloid, reduces cerebral glucose metabolism in normal aging. J. Neurosci. 32, 18227-18233 (2012).
59. Wolf, A. B., Caselli, R. J., Reiman, E. M. & Valla, J. APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease. Neurobiol. Aging S0197-4580, 00522-2 (2012).
60. Braak, H., Braak, E., Ohm, T. & Bohl, J. Silver impregnation of Alzheimer's neurofibrillary changes counterstained for basophilic material and lipofuscin pigment. Stain Technol. 63, 197-200 (1988).
61. Gallyas, F. Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol. Acad. Sci. Hung. 19, 1-8 (1971).
62. Molsa, P. K. et al. Validity of clinical diagnosis in dementia: a prospective clinicopathological study. J. Neurol. Neurosurg. Psychiatry 48, 1085-1090 (1985).
63. Mirra, S. S. et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486 (1991).
64. Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259 (1991).
65. Wenham, P. R., Price, W. H. & Blandell, G. Apolipoprotein E genotyping by one-stage PCR. Lancet 337, 1158-1159 (1991).